Aggregation and secondary loop structure of oligonucleotides do not determine their ability to inhibit TLR9

International Immunopharmacology

Volumn 11, Issue 8, 2011, Pages 1032-1037

  Ashman, Robert F ^a   Goeken, J Adam ^a   Lenert, Petar S ^a  

^a UNIVERSITY OF IOWA   (United States)

Author keywords

B lymphocytes; CpG DNA; Inhibitory oligonucleotides; Toll like receptor 9

Indexed keywords

CPG OLIGODEOXYNUCLEOTIDE; INHIBITORY OLIGONUCLEOTIDE; OLIGONUCLEOTIDE; TOLL LIKE RECEPTOR 9; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; ENDOSOME; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PH; POLYMERIZATION; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN SECONDARY STRUCTURE;

EID: 84860389924     PISSN: 15675769     EISSN: 18781705     Source Type: Journal    
DOI: 10.1016/j.intimp.2011.02.023     Document Type: Article

References (41)

1. Takeda K, Kaisho T, Akira S. Toll-like receptors. Annu Rev Immunol 2003;21: 335-76. (Pubitemid 37174535)
2. Hacker H, Mischak H, Miethke T, Liptay S, Schmid R, Sparwasser T, et al. CpG-DNAspecific activation of antigen-presenting cells requires stress kinase activity and is preceded by non-specific endocytosis and endosomal maturation. EMBO J 1998;17:6230-40. (Pubitemid 28497796)
3. Ahmad-Nejad P, Hacker H, Rutz M, Bauer S, Vabulas RM, Wagner H. Bacterial CpGDNA and lipopolysaccharides activate Toll-like receptors at distinct cellular compartments. Eur J Immunol 2002;32:1958-68. (Pubitemid 34814552)
4. Stacey KJ, Sweet MJ, Hume DA. Macrophages ingest and are activated by bacterial DNA. J Immunol 1996;157:2116-22. (Pubitemid 126449689)
5. Chaturvedi A, Dorward D, Pierce SK. The B cell receptor governs the subcellular location of Toll-like receptor 9 leading to hyperresponses to DNA-containing antigens. Immunity 2008;28:799-809.
6. Leadbetter EA, Rifkin IR, Hohlbaum AM, Beaudette BC, Schlomchik MJ, Marshak-Rothstein A. Chromatin-IgG complexes activate B cells by dual engagement of IgM and Toll-like receptors. Nature 2002;416:603-7. (Pubitemid 34406754)
7. Boulé MW, Broughton C, Mackay F, Akira S, Marshak-Rothstein A, Rifkin IR. Tolllike receptor 9-dependent and -independent dendritic cell activation by chromatin-immunoglobulin G complexes. J Exp Med 2004;199:1631-40. (Pubitemid 38821996)
8. Means TK, Latz E, Hayashi F, Murali MR, Golenbock DT, Luster AD. Human lupus autoantibody-DNA complexes activate DCs through cooperation of CD32 and TLR9. J Clin Invest 2005;115:407-17. (Pubitemid 40385482)
9. Brummel R, Roberts TL, Stacey KJ, Lenert P. Higher-order CpG-DNA stimulation reveals distinct activation requirements for marginal zone and follicular B cells in lupus mice. Eur J Immunol 2006;36:1951-62. (Pubitemid 44089060)
10. Barton GM, Kagan JC, Medzhitov R. Intracellular localization of Toll-like receptor 9 prevents recognition of self DNA but facilitates access to viral DNA. Nat Immunol 2006;7:13-5.
11. Latz E, Schoenemeyer A, Visintin A, Fitzgerald KA, Monks BG, Knetter CF, et al. TLR signals after translocating from the ER to CpG DNA in the lysosome. Nat Immunol 2004;5:190-8. (Pubitemid 38208361)
12. Brinkmann MM, Spooner E, Hoebe K, Beutler B, Ploegh HL, Kim YM. The interaction between the ER membrane protein UNC93B and TLR3, 7, and 9 is crucial for TLR signaling. J Cell Biol 2007;177:265-75. (Pubitemid 46658638)
13. Tabeta K, Hoebe K, Janssen EM, Du X, Georgel P, Crozat K, et al. The Unc93b1 mutation 3d disrupts exogenous antigen presentation and signaling via Toll-like receptors 3, 7 and 9. Nat Immunol 2006;7:156-64. (Pubitemid 43135881)
14. Krieg AM, Yi AK, Matson S, Waldschmidt TJ, Bishop GA, Teasdale R, et al. CpG motifs in bacterial DNA trigger direct B-cell activation. Nature 1995;374:546-9.
15. Krieg AM. CpG motifs in bacterial DNA and their immune effects. Annu Rev Immunol 2002;20:709-60. (Pubitemid 34293438)
16. Lenert P, Goeken JA, Ashman RF. Extended sequence preferences for oligodeoxyribonucleotide activity. Immunology 2006;117:474-81.
17. Halpern MD, Pisetsky DS. In vitro inhibition of murine IFN gamma production by phosphorothioate deoxyguanosine oligomers. Immunopharmacology 1995;29: 47-52.
18. Pisetsky DS, Reich CF. Inhibition of murine macrophage IL-12 production by natural and synthetic DNA. Clin Immunol 2000;96:198-204.
19. Zhu FG, Reich CF, Pisetsky DS. Inhibition of murine dendritic cell activation by synthetic phosphorothioate oligodeoxynucleotides. J Leukoc Biol 2002;72: 1154-63. (Pubitemid 36008886)
20. Krieg AM, Wu T, Weeratna R, Efler SM, Love-Homan L, Yang L, et al. Sequence motifs in adenoviral DNA block immune activation by stimulatory CpG motifs. Proc Natl Acad Sci USA 1998;95:12631-6. (Pubitemid 28483816)
21. Chen Y, Lenert P, Weeratna R, McCluskie M, Wu T, Davis HL, et al. Identification of methylated CpG motifs as inhibitors of the immune stimulatory CpG motifs. Gene Ther 2001;8:1024-32. (Pubitemid 32633379)
22. Stunz LL, Lenert P, Peckham D, Yi AK, Haxhinasto S, Chang M, et al. Inhibitory oligonucleotides specifically block effects of stimulatory CpG oligonucleotides in B cells. Eur J Immunol 2002;32:1212-22. (Pubitemid 34546248)
23. Ashman RF, Goeken JA, Drahos J, Lenert P. Sequence requirements for oligodeoxyribonucleotide inhibitory activity. Int Immunol 2005;17:411-20. (Pubitemid 40568116)
24. Lenert P, Rasmussen W, Ashman RF, Ballas ZK. Structural characterization of the inhibitory DNA motif for the type A(D)-CpG-induced cytokine secretion and NKcell lytic activity in mouse spleen cells. DNA Cell Biol 2003;22:621-31. (Pubitemid 37357732)
25. Ashman RF, Lenert P. Structural requirements and applications of inhibitory oligodeoxyribonucleotides. Immunol Res 2007;39:4-14. (Pubitemid 47574896)
26. Latz E, Verma A, Visintin A, Gong M, Sirois CM, Klein DC, et al. Ligand-induced conformational changes allosterically activate Toll-like receptor 9. Nat Immunol 2007;8:772-9. (Pubitemid 46965353)
27. Hartmann G, Krieg AM. Mechanism and function of a newly identified CpG DNA motif in human primary B cells. J Immunol 2000;164:944-53.
28. Hartmann G, Weeratna RD, Ballas ZK, Payette P, Blackwell S, Suparto I, et al. Delineation of a CpG phosphorothioate oligodeoxynucleotide for activating primate immune responses in vitro and in vivo. J Immunol 2000;164:1617-24. (Pubitemid 30067282)
29. Lenert P, Yasuda K, Busconi L, Nelson P, Fleenor C, Ratnabalasuriar RS, et al. DNA-like Class R inhibitory oligonucleotides (INH-ODNs) preferentially block autoantigeninduced B-cell and dendritic cell activation in vitro and autoantibody production in lupus-prone MRL-Faslpr/lpr mice in vivo. Arthritis Res Ther 2009;11:R79.
30. Laughlan G, Murchie AIH, Norman DG, Moore MH, Moody PCE, Lilley DMJ, et al. The high resolution crystal structure of a parallel-stranded guanine tetraplex. Science 1994;265:520-5.
31. Benemetskaya L, Berton M, Kolbanovsky A, Benimetsky S, Stein CA. Formation of a Gtetrad and higher order structures correlates with biological activity of the RelA (NF-κB p65) "antisense" oligodeoxynucleotide. Nucleic Acids Res 1997;25:2648-56. (Pubitemid 27298162)
32. Ashman RF, Goeken JA, Latz E, Lenert P. Optimal oligonucleotide sequences for TLR9 inhibitory activity in human cells: lack of correlation with TLR9-binding. Int Immunol. In press.
33. Yi AK, Peckham DW, Ashman RF, Krieg AM. CpG DNA rescues B cells from apoptosis by activating NFkappaB and preventing mitochondrial membrane potential disruption via a chloroquine-sensitive pathway. Int Immunol 1999;11:2015-24. (Pubitemid 30009161)
34. Wu CC, Lee J, Raz E, Corr M, Carson DA. Necessity of oligonucleotide aggregation for toll-like receptor 9 activation. J Biol Chem 2004;279:33071-8. (Pubitemid 39062950)
35. Duramad O, Fearon KL, Chang B, Chan JH, Gregorio J, Coffman RL, et al. Inhibitors of TLR-9 act on multiple cell subsets in mouse and man in vitro and prevent death in vivo from systemic inflammation. J Immunol 2005;174:5193-200. (Pubitemid 40593156)
36. Goeken JA, Layer T, Fleenor S, Laccheo M, Lenert P. B-cell receptor for antigen modulates B-cell responses to complex TLR9 agonists and antagonists: implications for systemic lupus erythematosus. Lupus 2010;19:1290-301.
37. Haas T, Metzger J, Schmitz F, Heit A, Müller T, Latz E, et al. The DNA sugar backbone 2' deoxyribose determines toll-like receptor 9 activation. Immunity 2008;28: 315-23. (Pubitemid 351335308)
38. Ewald SE, Lee BL, Lau L, Wickliffe KE, Shi G-P, Chapman HA, et al. The ectodomain of Toll-like receptor 9 is cleaved to generate a functional receptor. Nature 2008;456:658-62.
39. Sepulveda FE, Maschalidi S, Colisson R, Heslop L, Ghirelli C, Sakka E, et al. Critical role for asparagine endopeptidase in endocytic Toll-like receptor signaling in dendritic cells. Immunity 2009;31:737-48.
40. Lenert P, Stunz L, Yi AK, Krieg AM, Ashman RF. CpG stimulation of primary mouse B cells is blocked by inhibitory oligodeoxyribonucleotides at a site proximal to NF-κB activation. Antisense Nucleic Acid Drug Dev 2001;11:247-56. (Pubitemid 32852883)
41. Lenert P, Yi AK, Krieg AM, Stunz LL, Ashman RF. Inhibitory oligonucleotides block the induction of AP-1 transcription factor by stimulatory CpG oligonucleotides in B cells. Antisense Nucleic Acid Drug Dev 2003;13:143-50.